• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《2013年韩国HIV感染者的HIV/AIDS诊断与治疗临床指南》

The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.

出版信息

Infect Chemother. 2013 Dec;45(4):455-61. doi: 10.3947/ic.2013.45.4.455. Epub 2013 Dec 27.

DOI:10.3947/ic.2013.45.4.455
PMID:24475362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3902823/
Abstract

While a variety of clinical guidelines for the diagnosis and treatment of HIV/AIDS are used extensively around the world, the implementation of such guidelines is not assured in Korea due to constraints with respect to the diagnostic tests and antiretroviral drugs currently available in the country. Consequently, the Committee for Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS of the Korean Society for AIDS was founded in 2010, and the first edition of the Korean guidelines was published a year later. However, due to the rapid discovery of new data in the field of HIV and the evolution of the clinical environment in Korea in the last few years, it has become necessary to revise the first set of guidelines. This guideline aims to provide comprehensive information regarding the diagnosis and management of HIV/AIDS in Korea. The recommendations contain important information for physicians working with HIV/AIDS in the clinical field. A brief summary of the revised guidelines and key changes to the original version of the guidelines are summarized below.

摘要

虽然世界各地广泛使用各种关于艾滋病毒/艾滋病诊断和治疗的临床指南,但由于韩国目前可用的诊断测试和抗逆转录病毒药物存在限制,这些指南在韩国的实施无法得到保证。因此,韩国艾滋病协会艾滋病毒/艾滋病诊断和治疗临床指南委员会于2010年成立,一年后发布了第一版韩国指南。然而,由于近年来艾滋病毒领域新数据的迅速发现以及韩国临床环境的演变,有必要修订第一套指南。本指南旨在提供有关韩国艾滋病毒/艾滋病诊断和管理的全面信息。这些建议包含了临床领域从事艾滋病毒/艾滋病工作的医生的重要信息。修订指南的简要概述以及与原始版本指南的关键变化总结如下。

相似文献

1
The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.《2013年韩国HIV感染者的HIV/AIDS诊断与治疗临床指南》
Infect Chemother. 2013 Dec;45(4):455-61. doi: 10.3947/ic.2013.45.4.455. Epub 2013 Dec 27.
2
The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.《2015年韩国HIV感染者的HIV/AIDS诊断与治疗临床指南》
Infect Chemother. 2015 Sep;47(3):205-11. doi: 10.3947/ic.2015.47.3.205. Epub 2015 Sep 30.
3
The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections.《2015年韩国HIV感染者机会性感染治疗与预防临床指南:机会性感染指南》
Infect Chemother. 2016 Mar;48(1):54-60. doi: 10.3947/ic.2016.48.1.54. Epub 2016 Mar 31.
4
Summary of 2021 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans.2021年韩国HIV感染者的HIV/AIDS诊断与治疗临床指南摘要
Infect Chemother. 2021 Sep;53(3):592-616. doi: 10.3947/ic.2021.0305. Epub 2021 Aug 5.
5
Summary of Guidelines for the Use of Pre-Exposure Prophylaxis for HIV in Korea.韩国HIV暴露前预防使用指南摘要。
Infect Chemother. 2017 Sep;49(3):243-246. doi: 10.3947/ic.2017.49.3.243.
6
The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.《2018年韩国HIV感染者的HIV/AIDS诊断与治疗临床指南》
Infect Chemother. 2019 Mar;51(1):77-88. doi: 10.3947/ic.2019.51.1.77.
7
Tuberculosis结核病
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.成人HIV感染的抗逆转录病毒治疗:美国国际艾滋病协会专家组2008年建议
JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.
10
German-Austrian recommendations for HIV-therapy in pregnancy--common declaration of The German AIDS-society (DAIG), The Austrian AIDS-society (OEAG) as well as The Robert-Koch Institute Berlin (RKI), The German Association of Physicians specialized in HIV Care (DAGNAE), The German Society of Pediatric and Youth Medicine (DGKJ), The German AIDS Pediatric Association (PAAD), The German Society of Obstetrics and Gynecology (DGGG), The National Reference Center for Retroviruses (NRZ), German AIDS Assistance (DAH).德国-奥地利孕期艾滋病治疗建议——德国艾滋病协会(DAIG)、奥地利艾滋病协会(OEAG)、柏林罗伯特·科赫研究所(RKI)、德国艾滋病护理专家医师协会(DAGNAE)、德国儿科学与青少年医学学会(DGKJ)、德国艾滋病儿科学会(PAAD)、德国妇产科学会(DGGG)、国家逆转录病毒参考中心(NRZ)、德国艾滋病援助组织(DAH)的共同声明
Eur J Med Res. 2002 Oct 29;7(10):417-33.

引用本文的文献

1
Barriers and facilitators on the HIV care continuum among adults living with HIV in high-income countries: a scoping review protocol.高收入国家成人 HIV 感染者 HIV 护理连续体的障碍和促进因素:范围综述方案。
Syst Rev. 2022 Oct 15;11(1):222. doi: 10.1186/s13643-022-02097-x.
2
Patterns and prognosis of holding regimens for people living with HIV in Asian countries.亚洲国家艾滋病毒感染者维持治疗方案的模式和预后。
PLoS One. 2022 Mar 30;17(3):e0264157. doi: 10.1371/journal.pone.0264157. eCollection 2022.
3
Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea.单片治疗方案对韩国初治 HIV/AIDS 患者处方趋势的影响。
Sci Rep. 2022 Feb 7;12(1):2031. doi: 10.1038/s41598-022-06005-0.
4
Assessment of Human Immunodeficiency Virus Care Continuum in Korea using the National Health Insurance System Data.利用国民健康保险系统数据评估韩国的人类免疫缺陷病毒照护连续体
Infect Chemother. 2021 Sep;53(3):477-488. doi: 10.3947/ic.2021.0025.
5
A comparison of medication adherence and viral suppression in antiretroviral treatment-naïve patients with HIV/AIDS depending on the drug formulary.比较依达拉奉与依达拉奉联合脑苷肌肽治疗急性脑梗死的疗效和安全性
PLoS One. 2021 Jan 8;16(1):e0245185. doi: 10.1371/journal.pone.0245185. eCollection 2021.
6
Survival Trend of HIV/AIDS Patients Starting Antiretroviral Therapy in South Korea between 2001 and 2015.2001 至 2015 年韩国开始抗逆转录病毒疗法的艾滋病毒/艾滋病患者的生存趋势。
Yonsei Med J. 2020 Aug;61(8):705-711. doi: 10.3349/ymj.2020.61.8.705.
7
Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region.亚洲地区HIV阳性人群中的心血管疾病及心血管疾病风险
Open AIDS J. 2017 Aug 21;11:52-66. doi: 10.2174/1874613601711010052. eCollection 2017.
8
Trend of CD4+ Cell Counts at Diagnosis and Initiation of Highly Active Antiretroviral Therapy (HAART): Korea HIV/AIDS Cohort Study, 1992-2015.诊断时及开始高效抗逆转录病毒治疗(HAART)时CD4 + 细胞计数的趋势:韩国1992 - 2015年艾滋病毒/艾滋病队列研究
Infect Chemother. 2017 Jun;49(2):101-108. doi: 10.3947/ic.2017.49.2.101. Epub 2017 Jun 1.
9
Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.利益相关者参与艾滋病治愈研究:从其他艾滋病干预措施中吸取的经验教训及未来方向。
AIDS Patient Care STDS. 2015 Jul;29(7):389-99. doi: 10.1089/apc.2014.0348. Epub 2015 May 18.

本文引用的文献

1
Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.第 96 周时,在 ECHO 和 THRIVE 这两项 3 期、随机、双盲临床试验中,对基线病毒载量≤100000 拷贝/毫升的 HIV-1 感染患者进行利匹韦林或依非韦伦分析。
HIV Med. 2014 Jan;15(1):57-62. doi: 10.1111/hiv.12071. Epub 2013 Aug 28.
2
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.在初治 HIV-1 感染患者中,与依非韦伦相比,联合替诺福韦/恩曲他滨时,拉替拉韦具有持久的疗效和安全性:STARTMRK 的最终 5 年结果。
J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69.
3
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.利匹韦林与依非韦伦治疗基线病毒载量 100000 拷贝/ml 或以下的 HIV-1 感染者:第 48 周的 III 期分析。
AIDS. 2013 Mar 27;27(6):889-897. doi: 10.1097/QAD.0b013e32835e1554.
4
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.ARTEMIS 试验中,初治 HIV-1 感染患者中每日一次达芦那韦/利托那韦与洛匹那韦/利托那韦相比的最终 192 周疗效和安全性。
HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23.
5
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.在原发性 HIV-1 感染期间早期进行抗逆转录病毒治疗,会导致治疗中断后病毒设定点短暂下降。
PLoS One. 2011;6(11):e27463. doi: 10.1371/journal.pone.0027463. Epub 2011 Nov 15.
6
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.1型人类免疫缺陷病毒血清转化者开始高效抗逆转录病毒治疗的时机与临床结局
Arch Intern Med. 2011 Sep 26;171(17):1560-9. doi: 10.1001/archinternmed.2011.401.
7
Prevention of HIV-1 infection with early antiretroviral therapy.早期抗逆转录病毒疗法预防 HIV-1 感染。
N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.
8
Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.原发性HIV-1感染期间早期抗逆转录病毒疗法对细胞相关HIV-1 DNA和血浆HIV-1 RNA的影响。
Antivir Ther. 2011;16(4):535-45. doi: 10.3851/IMP1776.
9
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.长期替诺福韦治疗对同时感染人类免疫缺陷病毒和乙型肝炎病毒的患者有效。
Gastroenterology. 2010 Dec;139(6):1934-41. doi: 10.1053/j.gastro.2010.08.045. Epub 2010 Aug 26.
10
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.抗逆转录病毒治疗中断后 HIV-乙型肝炎病毒合并感染患者中乙型肝炎病毒频繁反弹。
AIDS. 2010 Mar 27;24(6):857-65. doi: 10.1097/QAD.0b013e328334bddb.